Compare NCRA & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCRA | CING |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 26.4M |
| IPO Year | N/A | 2021 |
| Metric | NCRA | CING |
|---|---|---|
| Price | $1.22 | $4.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 45.2K | ★ 119.5K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,106,275.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $3.20 |
| 52 Week High | $2.40 | $6.01 |
| Indicator | NCRA | CING |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 71.13 |
| Support Level | $0.83 | $3.75 |
| Resistance Level | $0.95 | $4.02 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 85.11 | 96.30 |
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.